stockrow
Friday 6 November 2026
Export KOD’s income statement to Excel — free account
Kodiak Sciences Inc.
- EPS
- −1.94%
- Free cash flow
- −33.9%
Quarter to June 2026, against a year earlier
98.85
7.83
+8.60%
Follow KOD
Alert me
Kodiak Sciences Inc. (KOD) EBITDA
Kodiak Sciences Inc.'s EBITDA for fiscal 2025 was −$208.1M, compared with −$160.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$220.8M. Over the past ten years it has ranged from −$331.4M (fiscal 2022) to −$16.9M (fiscal 2016); the current reading is higher than 40% of that period. Kodiak Sciences Inc. ranks 523rd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$208.1M | — |
| FY2024 | −$160.1M | — |
| FY2023 | −$252.2M | — |
| FY2022 | −$331.4M | — |
| FY2021 | −$258.3M | — |
| FY2020 | −$131.8M | — |
| FY2019 | −$48.5M | — |
| FY2018 | −$25.9M | — |
| FY2017 | −$25.0M | — |
| FY2016 | −$16.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$60.7M | — |
| Mar 2026 | −$53.4M | — |
| Dec 2025 | −$50.9M | — |
| Sep 2025 | −$55.8M | — |
| 31 more quarters | Free account |
Against its own ten years
Low −$331.4M
High −$16.9M
Ten-year median
−$146.0M
Current reading's percentile
40
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $191.8M |
| LGND Ligand Pharmaceuticals Incorporated compare | $57.3M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$158.0M |
| KOD Kodiak Sciences Inc. | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| IMVT Immunovant, Inc. compare | −$565.6M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$579.9M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item